Addition of CDK 4/6 inhibitor benefits patients with HR+, HER2+ metastatic breast cancer, new study shows
January 29, 2026
January 29, 2026
BOSTON, Massachusetts, Jan. 29 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:
* * *
Addition of CDK 4/6 inhibitor benefits patients with HR+, HER2+ metastatic breast cancer, new study shows
*
The addition of a CDK 4/6 inhibitor to standard therapy in patients with "double-positive" metastatic breast cancer significantly extended the time the disease did not progress according to data pub . . .
* * *
Addition of CDK 4/6 inhibitor benefits patients with HR+, HER2+ metastatic breast cancer, new study shows
*
The addition of a CDK 4/6 inhibitor to standard therapy in patients with "double-positive" metastatic breast cancer significantly extended the time the disease did not progress according to data pub . . .